Key Points
- Labcorp EVP Kathryn Kyle sold 762 shares on June 8 at an average price of $263.89, totaling about $201,084. The transaction, made under a pre-arranged 10b5-1 plan, reduced her ownership by 16.66%.
- The company recently beat earnings expectations, reporting $4.25 EPS versus the $4.09 consensus and revenue of $3.54 billion, up 5.8% year over year. Labcorp also reiterated FY 2026 EPS guidance of 17.700-18.350.
- Labcorp declared a quarterly dividend of $0.72 per share, payable June 11, which annualizes to $2.88 and yields about 1.1%. Institutional ownership remains high at 95.94%, and analysts currently rate the stock a “Moderate Buy.”
Labcorp Holdings Inc. (NYSE:LH - Get Free Report) EVP Kathryn Kyle sold 762 shares of Labcorp stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $263.89, for a total value of $201,084.18. Following the completion of the sale, the executive vice president directly owned 3,813 shares in the company, valued at $1,006,212.57. This trade represents a 16.66% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Labcorp Trading Down 1.0%
Shares of LH stock opened at $268.52 on Thursday. The stock's 50-day moving average price is $262.84 and its 200-day moving average price is $265.78. The company has a current ratio of 1.73, a quick ratio of 1.54 and a debt-to-equity ratio of 0.68. Labcorp Holdings Inc. has a 12-month low of $241.81 and a 12-month high of $293.72. The stock has a market capitalization of $22.02 billion, a price-to-earnings ratio of 23.78, a price-to-earnings-growth ratio of 1.90 and a beta of 0.90.
Labcorp (NYSE:LH - Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share for the quarter, topping the consensus estimate of $4.09 by $0.16. Labcorp had a return on equity of 16.29% and a net margin of 6.66%.The company had revenue of $3.54 billion for the quarter, compared to analysts' expectations of $3.51 billion. During the same period in the previous year, the firm posted $3.84 earnings per share. The firm's revenue for the quarter was up 5.8% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Equities research analysts predict that Labcorp Holdings Inc. will post 18 EPS for the current fiscal year.
Labcorp Announces Dividend
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Shareholders of record on Friday, May 29th will be paid a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 1.1%. The ex-dividend date of this dividend is Friday, May 29th. Labcorp's payout ratio is presently 25.51%.
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Brighton Jones LLC bought a new position in shares of Labcorp during the 4th quarter worth $991,000. Integrated Wealth Concepts LLC lifted its stake in Labcorp by 7.9% in the first quarter. Integrated Wealth Concepts LLC now owns 2,427 shares of the medical research company's stock worth $565,000 after acquiring an additional 177 shares during the period. Goldman Sachs Group Inc. lifted its stake in Labcorp by 52.2% in the first quarter. Goldman Sachs Group Inc. now owns 353,843 shares of the medical research company's stock worth $82,353,000 after acquiring an additional 121,304 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in Labcorp in the second quarter worth about $5,873,000. Finally, First Trust Advisors LP lifted its stake in Labcorp by 83.2% in the second quarter. First Trust Advisors LP now owns 86,046 shares of the medical research company's stock worth $22,588,000 after acquiring an additional 39,087 shares during the period. Institutional investors own 95.94% of the company's stock.
Analyst Ratings Changes
Several brokerages have weighed in on LH. Evercore reissued an "outperform" rating and set a $300.00 price objective on shares of Labcorp in a research note on Wednesday, April 8th. JPMorgan Chase & Co. upped their target price on Labcorp from $319.00 to $330.00 and gave the company an "overweight" rating in a research note on Wednesday, February 18th. Wall Street Zen raised Labcorp from a "hold" rating to a "buy" rating in a research note on Saturday, May 2nd. Robert W. Baird set a $334.00 target price on Labcorp in a research note on Friday, May 1st. Finally, Morgan Stanley reaffirmed an "overweight" rating on shares of Labcorp in a research note on Tuesday, February 17th. Eight research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $308.00.
Get Our Latest Stock Analysis on LH
Labcorp Company Profile
(
Get Free Report)
Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.
Labcorp's core businesses encompass clinical laboratory testing and pharmaceutical development services.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
